Disorder of thyroid
Methodology & AI Transparency ⓘ
Disorder of thyroid Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Thyroid, Adrenal & Endocrine Disorders practice, Disorder of thyroid (ICD-10 E07.9) is stratified through morning pituitary-target hormone in Disorder of thyroid (E07.9: axis assays), pairing targeted symptom control with longitudinal Free Thyroxine (Free in Disorder of thyroid (E07.9: T4) & Free) surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code E07.9 categorizes Disorder of thyroid under Thyroid, Adrenal & Endocrine Disorders.
- 3 Typical cash cost range: Primary evaluation for Disorder of thyroid incorporates morning pituitary-target hormone in Disorder of thyroid (E07.9: axis assays) and symptom diary review.
- 4 Top reported side effects / signs: Key Thyroid & Endocrine biomarkers for Disorder of thyroid (E07.9): Thyroid-Stimulating Hormone (TSH) [Disorder of thyroid E07.9] & Free Thyroxine (Free in Disorder of thyroid (E07.9: T4) & Free) (FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E07.9)).
Ask our AI Specialists anything about Disorder of thyroid
What Is Disorder of thyroid?
Within Thyroid, Adrenal & Endocrine Disorders practice, Disorder of thyroid (ICD-10 E07.9) is stratified through morning pituitary-target hormone in Disorder of thyroid (E07.9: axis assays), pairing targeted symptom control with longitudinal Free Thyroxine (Free in Disorder of thyroid (E07.9: T4) & Free) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Disorder of thyroid (E07.9, Thyroid & Endocrine) reflects hypothalamic-pituitary-endocrine feedback dysregulation [Disorder of thyroid E07.9]. longitudinal control is benchmarked via Thyroid-Stimulating Hormone (TSH) [Disorder of thyroid E07.9].
Common Symptoms & Clinical Signs
- • Presentation of Disorder of thyroid (E07.9): unexplained shifts in in Disorder of thyroid (E07.9: cold/heat tolerance, basal)
- • Secondary Disorder of thyroid clinical sign: persistent fatigue, sluggish in Disorder of thyroid (E07.9: morning waking, or)
- • Symptom flares in Disorder of thyroid correlating with Thyroid-Stimulating Hormone (TSH) [Disorder of thyroid E07.9] deviation outside 0.8 – 2.5 mIU/L (E07.9)
- • Functional thyroid & endocrine impact requiring morning pituitary-target hormone in Disorder of thyroid (E07.9: axis assays) evaluation (E07.9)
Disorder of thyroid Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E07.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Thyroid, Adrenal & Endocrine Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Thyroid-Stimulating Hormone (TSH) [Disorder of thyroid E07.9] | 0.8 – 2.5 mIU/L (E07.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Free Thyroxine (Free in Disorder of thyroid (E07.9: T4) & Free) | FT4 1.1–1.6 ng/dL; FT3 3.0–4.0 pg/mL (E07.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Morning Serum Cortisol in Disorder of thyroid (E07.9: (8 AM)) | 10 – 18 mcg/dL (E07.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Disorder of thyroid
Treatment selection for Disorder of thyroid depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Disorder of thyroid)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake: What a 10,039-Participant Study Found Higher doses of SSRIs appear slightly more effective in depression. The American journal of psychiatry • 2016-02-01 • Meta-Analysis | N = 10,039 | 99/100 | PMID 26552940 ↗ |
| New Insights on Pharmacological and non-pharmacological treatments for depression in: What a 10,991-Participant Study Found Herbal medicine and mirtazapine had no significant difference in overall risk of side effects compared with placebo. Psychiatry research • 2019-11-15 • Meta-Analysis | N = 10,991 | 99/100 | PMID 31627074 ↗ |
| New Insights on Antidepressants for the treatment of adults with depression in the maintenance: What a 9,384-Participant Study Found Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. Molecular psychiatry • 2023-01-15 • Meta-Analysis | N = 9,384 | 99/100 | PMID 36253442 ↗ |
| New Insights on Modeling the efficacy of a novel antidepressant zuranolone for: What a 8,735-Participant Study Found Primary side effects related to zuranolone included somnolence, headache, dizziness, and sedation, with no severe safety signals observed. Journal of affective disorders • 2026-01-01 • Meta-Analysis | N = 8,735 | 99/100 | PMID 40876640 ↗ |
| New Insights on Comparative efficacy and acceptability of anxiolytic drugs for the treatment of: What a 28,637-Participant Study Found This network meta-analysis provides a unique comparison of the efficacy and acceptability of anxiolytics. European archives of psychiatry and clinical neuroscience • 2026-06-15 • Meta-Analysis | N = 28,637 | 99/100 | PMID 40788541 ↗ |
Disorder of thyroid Patient Community & “People Like Me” Threads
Filter Disorder of thyroid community threads and patient logs by age, biological sex, dosage, and treatment duration.